Celcuity, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US15102K1007
USD
105.87
8.37 (8.58%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

783.47 k

Shareholding (Mar 2025)

FII

2.07%

Held by 29 FIIs

DII

72.25%

Held by 21 DIIs

Promoter

8.79%

How big is Celcuity, Inc.?

22-Jun-2025

As of Jun 18, Celcuity, Inc. has a market capitalization of 446.07 million, with net sales of 0.00 million and a net profit of -127.16 million over the latest four quarters. Shareholder's funds are reported at 115.62 million, and total assets amount to 245.12 million.

As of Jun 18, Celcuity, Inc. has a market capitalization of 446.07 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is -127.16 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 115.62 million, and total assets amount to 245.12 million.

Read More

What does Celcuity, Inc. do?

22-Jun-2025

Celcuity, Inc. is a cellular analysis company focused on identifying new cancer sub-types and developing diagnostic tests to enhance treatment outcomes for cancer patients. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $446 million and reported a net profit loss of $37 million as of March 2025.

Overview: <BR>Celcuity, Inc. is a cellular analysis company focused on discovering new cancer sub-types and commercializing diagnostic tests to improve clinical outcomes for cancer patients treated with targeted therapies, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -37 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 446.07 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.23 <BR>Return on Equity: -146.72% <BR>Price to Book: 5.15<BR><BR>Contact Details: <BR>Address: 16305 36th Ave N Ste 100, MINNEAPOLIS MN: 55446-4285 <BR>Tel: 1 763 3920767 <BR>Fax: 1 302 6555049 <BR>Website: http://celcuity.com/

Read More

Is Celcuity, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Celcuity, Inc. shows a mildly bullish trend with bullish MACD and KST indicators, despite bearish RSI readings, having outperformed the S&P 500 year-to-date but underperformed over the last month.

As of 10 October 2025, the technical trend for Celcuity, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the RSI is bearish on both weekly and monthly time frames. Bollinger Bands indicate a mildly bullish stance on both weekly and monthly charts. Daily moving averages are also mildly bullish. According to Dow Theory, there is no trend on the weekly chart, but it is bullish on the monthly chart. <BR><BR>In terms of performance, Celcuity has significantly outperformed the S&P 500 year-to-date with a return of 262.18% compared to the S&P 500's 11.41%. However, it has underperformed the benchmark over the last month, with a return of -13.66% against the S&P 500's 0.31%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and KST indicators, despite the bearish RSI readings.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,653 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.55

stock-summary
Return on Equity

-335.12%

stock-summary
Price to Book

59.78

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-45 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
95.33%
0%
95.33%
6 Months
786.68%
0%
786.68%
1 Year
744.26%
0%
744.26%
2 Years
611.49%
0%
611.49%
3 Years
1183.27%
0%
1183.27%
4 Years
713.76%
0%
713.76%
5 Years
946.15%
0%
946.15%

Celcuity, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-272.40%
EBIT to Interest (avg)
-13.84
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.23
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
99.79%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.70
EV to EBIT
-3.05
EV to EBITDA
-3.05
EV to Capital Employed
-19.05
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-146.72%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 29 Schemes (16.89%)

Foreign Institutions

Held by 29 Foreign Institutions (2.07%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -91.14% vs -62.33% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-44.00",
          "val2": "-24.30",
          "chgp": "-81.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.20",
          "val2": "2.30",
          "chgp": "39.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-45.30",
          "val2": "-23.70",
          "chgp": "-91.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -75.24% vs -57.92% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-113.10",
          "val2": "-66.10",
          "chgp": "-71.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "10.30",
          "val2": "5.30",
          "chgp": "94.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-111.80",
          "val2": "-63.80",
          "chgp": "-75.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-44.00
-24.30
-81.07%
Interest
3.20
2.30
39.13%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-45.30
-23.70
-91.14%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -91.14% vs -62.33% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-113.10
-66.10
-71.10%
Interest
10.30
5.30
94.34%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-111.80
-63.80
-75.24%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -75.24% vs -57.92% in Dec 2023

stock-summaryCompany CV
About Celcuity, Inc. stock-summary
stock-summary
Celcuity, Inc.
Pharmaceuticals & Biotechnology
Celcuity, Inc. is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it. CELx platform provides traditional molecular diagnostics, which provides a snapshot of the genetic mutations present in a patient’s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival.
Company Coordinates stock-summary
Company Details
16305 36th Ave N Ste 100 , MINNEAPOLIS MN : 55446-4285
stock-summary
Tel: 1 763 3920767
stock-summary
Registrar Details